Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy

OBJECTIVE: To compare total medical costs and utilization over a 12-month period in commercially insured patients receiving FDA-approved adjunctive atypical antipsychotics (aripiprazole, olanzapine, or quetiapine) for depression. METHODS: A retrospective claims analysis was conducted from 2005–2010...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadkarni, Anagha, Kalsekar, Iftekhar, You, Min, Forbes, Robert, Hebden, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553650/
https://www.ncbi.nlm.nih.gov/pubmed/23378778
http://dx.doi.org/10.2147/CEOR.S36526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553650/
https://www.ncbi.nlm.nih.gov/pubmed/23378778
http://dx.doi.org/10.2147/CEOR.S36526

Ejemplares similares